- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-Flag magnetic beads
- Anti-Flag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Magnetic Separator
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
GSK269962A HCl
Synonyms: GSK269962B, GSK269962
GSK269962A HCl is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
GSK269962A HCl Chemical Structure
CAS No. 2095432-71-4
Purity & Quality Control
Batch:
Purity:
99.59%
99.59
GSK269962A HCl Related Products
| Related Targets | ROCK1 ROCK2 | Click to Expand |
|---|---|---|
| Related Products | Y-27632 2HCl Y-27632 Fasudil HCl Thiazovivin GSK429286A RKI-1447 Ripasudil hydrochloride dihydrate Y-39983 Dihydrochloride Hydroxyfasudil HCl | Click to Expand |
| Related Compound Libraries | Kinase Inhibitor Library PI3K/Akt Inhibitor Library MAPK Inhibitor Library DNA Damage/DNA Repair compound Library Cell Cycle compound library | Click to Expand |
Signaling Pathway
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=18.8477 μM | SANGER | |||
| NCI-H1694 | Growth inhibition assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50=24.8749 μM | SANGER | |||
| NCI-H1963 | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=1.27839 μM | SANGER | |||
| NCI-H2081 | Growth inhibition assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50=34.6044 μM | SANGER | |||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=22.6272 μM | SANGER | |||
| NCI-H2107 | Growth inhibition assay | Inhibition of human NCI-H2107 cell growth in a cell viability assay, IC50=25.6561 μM | SANGER | |||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=6.50426 μM | SANGER | |||
| NCI-H2171 | Growth inhibition assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50=0.95937 μM | SANGER | |||
| NCI-H2227 | Growth inhibition assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50=7.88616 μM | SANGER | |||
| NCI-H524 | Growth inhibition assay | Inhibition of human NCI-H524 cell growth in a cell viability assay, IC50=22.8763 μM | SANGER | |||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=18.5431 μM | SANGER | |||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=2.45161 μM | SANGER | |||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=15.0578 μM | SANGER | |||
| NOS-1 cell | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=5.82294 μM | SANGER | |||
| OCI-AML2 cell | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=10.9496 μM | SANGER | |||
| OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=17.201 μM | SANGER | |||
| ONS-76 cell | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=13.9191 μM | SANGER | |||
| OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=46.195 μM | SANGER | |||
| OVCAR-4 cell | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=8.71808 μM | SANGER | |||
| P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=7.62877 μM | SANGER | |||
| P30-OHK cell | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=7.04954 μM | SANGER | |||
| PSN1 cell | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50=6.22126 μM | SANGER | |||
| QIMR-WIL cell | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=0.49004 μM | SANGER | |||
| RCC10RGB cell | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=18.9036 μM | SANGER | |||
| RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=10.5662 μM | SANGER | |||
| RL95-2 cell | Growth inhibition assay | Inhibition of human RL95-2 cell growth in a cell viability assay, IC50=10.67 μM | SANGER | |||
| RPMI-6666 cell | Growth inhibition assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=18.5236 μM | SANGER | |||
| RPMI-8402 cell | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=4.5856 μM | SANGER | |||
| RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.393 μM | SANGER | |||
| Ramos-2G6-4C10 cell | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=1.357 μM | SANGER | |||
| SCLC-21H cell | Growth inhibition assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50=7.61149 μM | SANGER | |||
| SF126 cell | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=11.8321μM | SANGER | |||
| SF268 cell | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=6.23183 μM | SANGER | |||
| SF539 cell | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50=1.28661 μM | SANGER | |||
| SH-4 cell | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50=5.75508 μM | SANGER | |||
| SIG-M5 cell | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=11.7259 μM | SANGER | |||
| SJSA-1 cell | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=1.04526 μM | SANGER | |||
| SK-LMS-1 cell | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=32.5965 μM | SANGER | |||
| SK-MM-2 cell | Growth inhibition assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50=42.3405 μM | SANGER | |||
| SK-N-DZ cell | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=9.48314 μM | SANGER | |||
| SK-NEP-1 cell | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=17.5456 μM | SANGER | |||
| SK-PN-DW cell | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=24.9736 μM | SANGER | |||
| SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=8.07737 μM | SANGER | |||
| SR cell | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=0.000137 μM | SANGER | |||
| SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=12.7336 μM | SANGER | |||
| SW684 cell | Growth inhibition assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50=39.011 μM | SANGER | |||
| SW872 cell | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=0.88656 μM | SANGER | |||
| SW962 cell | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50=12.7521 μM | SANGER | |||
| 697 cell | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=0.2991 μM | SANGER | |||
| 8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=23.0793 μM | SANGER | |||
| A101D cell | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50=1.87034 μM | SANGER | |||
| ACN cell | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50=21.4387 μM | SANGER | |||
| AM-38 cell | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50=7.26327 μM | SANGER | |||
| ATN-1 cell | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=24.7555 μM | SANGER | |||
| BB30-HNC cell | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=22.2532 μM | SANGER | |||
| BB49-HNC cell | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=0.00789 μM | SANGER | |||
| human BC-1 cell | Growth inhibition assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50=3.97107 μM | SANGER | |||
| BE-13 cell | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.14081μM | SANGER | |||
| BL-70 cell | Growth inhibition assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50=3.40703 μM | SANGER | |||
| BV-173 cell | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=18.8859 μM | SANGER | |||
| Becker cell | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50=13.9545 μM | SANGER | |||
| CAL-148 cell | Growth inhibition assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50=35.6557 μM | SANGER | |||
| TE-10 cell | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=22.8423 μM | SANGER | |||
| TE-12 cell | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50=32.4114 μM | SANGER | |||
| TE-8 cell | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=11.6089 μM | SANGER | |||
| TE-9 cell | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50=36.6381 μM | SANGER | |||
| TGW cell | Growth inhibition assay | Inhibition of human TGW cell growth in a cell viability assay, IC50=23.3577 μM | SANGER | |||
| UACC-257 cell | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=8.70625 μM | SANGER | |||
| WSU-NHL cell | Growth inhibition assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=27.1907 μM | SANGER | |||
| no-10 cell | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50=0.66846 μM | SANGER | |||
| no-11 cell | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50=47.0263 μM | SANGER | |||
| CAS-1 cell | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=0.847 μM | SANGER | |||
| CCRF-CEM cell | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=8.65392 μM | SANGER | |||
| CMK cell | Growth inhibition assay | Inhibition of human CMK cell growth in a cell viability assay, IC50=1.01323 μM | SANGER | |||
| COLO-829 cell | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=3.24226 μM | SANGER | |||
| COR-L279 cell | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=2.0738 μM | SANGER | |||
| CP66-MEL cell | Growth inhibition assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=36.5497 μM | SANGER | |||
| CRO-AP2 cell | Growth inhibition assay | Inhibition of human CRO-AP2 cell growth in a cell viability assay, IC50=2.36088 μM | SANGER | |||
| CTV-1 cell | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=23.9145 μM | SANGER | |||
| Calu-6 cell | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=47.586 μM | SANGER | |||
| D-247MG cell | Growth inhibition assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50=0.62814 μM | SANGER | |||
| D-263MG cell | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50=0.08509 μM | SANGER | |||
| D-336MG cell | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50=0.62854 μM | SANGER | |||
| D-392MG cell | Growth inhibition assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50=1.43039 μM | SANGER | |||
| D-502MG cell | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50=8.53492 μM | SANGER | |||
| D-542MG cell | Growth inhibition assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50=12.3152 μM | SANGER | |||
| DB cell | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50=47.1417 μM | SANGER | |||
| DEL cell | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50=7.01898 μM | SANGER | |||
| DMS-114 cell | Growth inhibition assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50=49.8468 μM | SANGER | |||
| DMS-153 cell | Growth inhibition assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50=42.9923 μM | SANGER | |||
| DOHH-2 cell | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=4.22764 μM | SANGER | |||
| DSH1 cell | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50=8.43623 μM | SANGER | |||
| Daudi cell | Growth inhibition assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50=2.09802 μM | SANGER | |||
| EC-GI-10 cell | Growth inhibition assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50=44.2589 μM | SANGER | |||
| ECC4 cell | Growth inhibition assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50=32.1896 μM | SANGER | |||
| EM-2 cell | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=2.45594 μM | SANGER | |||
| ES1 cell | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50=5.54087 μM | SANGER | |||
| ES3 cell | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=42.4729 μM | SANGER | |||
| ES4 cell | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50=35.195 μM | SANGER | |||
| ES6 cell | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50=0.24733 μM | SANGER | |||
| ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=5.23124 μM | SANGER | |||
| ES8 cell | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=0.81924 μM | SANGER | |||
| EW-18 cell | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50=13.6759 μM | SANGER | |||
| EW-22 cell | Growth inhibition assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50=47.7947 μM | SANGER | |||
| GCIY cell | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50=9.80389 μM | SANGER | |||
| GDM-1 cell | Growth inhibition assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=8.39196 μM | SANGER | |||
| GI-1 cell | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50=0.00523 μM | SANGER | |||
| GI-ME-N cell | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=0.04951 μM | SANGER | |||
| GR-ST cell | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50=13.7902 μM | SANGER | |||
| GT3TKB cell | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50=1.60389 μM | SANGER | |||
| HAL-01 cell | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=6.69712 μM | SANGER | |||
| HCC1599 cell | Growth inhibition assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50=37.6011 μM | SANGER | |||
| HCC2218 cell | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=13.3834 μM | SANGER | |||
| HD-MY-Z cell | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=25.2146 μM | SANGER | |||
| HL-60 cell | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=12.2114 μM | SANGER | |||
| HOP-62 cell | Growth inhibition assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=23.9527 μM | SANGER | |||
| HT cell | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50=4.44321 μM | SANGER | |||
| HT-144 cell | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50=4.90686 μM | SANGER | |||
| HUTU-80 cell | Growth inhibition assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=3.78986 μM | SANGER | |||
| IST-MEL1 cell | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=32.9086 μM | SANGER | |||
| IST-SL1 cell | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=2.17079 μM | SANGER | |||
| IST-SL2 cell | Growth inhibition assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=3.26608 μM | SANGER | |||
| K052 cell | Growth inhibition assay | Inhibition of human K052 cell growth in a cell viability assay, IC50=0.75301 μM | SANGER | |||
| K5 cell | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50=33.5915 μM | SANGER | |||
| KALS-1 cell | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=29.3969 μM | SANGER | |||
| KARPAS-422 cell | Growth inhibition assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=42.9142 μM | SANGER | |||
| KARPAS-45 cell | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=4.11247 μM | SANGER | |||
| KE-37 cell | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=9.835 μM | SANGER | |||
| KG-1 cell | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50=23.9757 μM | SANGER | |||
| KGN cell | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50=0.56742 μM | SANGER | |||
| KM12 cell | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50=3.52964 μM | SANGER | |||
| KMOE-2 cell | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=30.4549 μM | SANGER | |||
| KNS-42 cell | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50=8.81915 μM | SANGER | |||
| KNS-81-FD cell | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50=37.426 μM | SANGER | |||
| KS-1 cell | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=0.0046 μM | SANGER | |||
| KU812 cell | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=23.484 μM | SANGER | |||
| L-540 cell | Growth inhibition assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50=20.7445 μM | SANGER | |||
| LAMA-84 cell | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=13.6742 μM | SANGER | |||
| LB1047-RCC cell | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=28.3883 μM | SANGER | |||
| LB2241-RCC cell | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=10.5536 μM | SANGER | |||
| LB2518-MEL cell | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=1.71496μM | SANGER | |||
| LB831-BLC cell | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=11.1726 μM | SANGER | |||
| LB996-RCC cell | Growth inhibition assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=12.7431 μM | SANGER | |||
| LC4-1 cell | Growth inhibition assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50=32.8341 μM | SANGER | |||
| LOUCY cell | Growth inhibition assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50=1.15276 μM | SANGER | |||
| LOXIMVI cell | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=30.2122 μM | SANGER | |||
| LS-123 cell | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50=39.2258 μM | SANGER | |||
| LU-134-A cell | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=7.14068 μM | SANGER | |||
| LU-139 cell | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=22.218 μM | SANGER | |||
| LXF-289 cell | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=17.4351μM | SANGER | |||
| MC116 cell | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50=45.0841 μM | SANGER | |||
| MDA-MB-134-VI cell | Growth inhibition assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50=39.2486 μM | SANGER | |||
| MFH-ino cell | Growth inhibition assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=0.64383 μM | SANGER | |||
| MHH-NB-11 cell | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50=0.0669 μM | SANGER | |||
| ML-2 cell | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=3.40304 μM | SANGER | |||
| MOLT-13 cell | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=4.43653 μM | SANGER | |||
| MOLT-16 cell | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=4.11163 μM | SANGER | |||
| MOLT-4 cell | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=14.4124 μM | SANGER | |||
| MPP-89 cell | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=1.25922 μM | SANGER | |||
| MRK-nu-1 cell | Growth inhibition assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=0.57572 μM | SANGER | |||
| MSTO-211H cell | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=12.869 μM | SANGER | |||
| MV-4-11 cell | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | |||
| NALM-6 cell | Growth inhibition assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=1.56109 μM | SANGER | |||
| NB1 cell | Growth inhibition assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50=3.84369 μM | SANGER | |||
| NB10 cell | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | |||
| NB12 cell | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50=16.5656 μM | SANGER | |||
| NB13 cell | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50=2.31278 μM | SANGER | |||
| NB17 cell | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50=3.58051 μM | SANGER | |||
| NB6 cell | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50=0.59114 μM | SANGER | |||
| NCCIT cell | Growth inhibition assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50=41.8453 μM | SANGER | |||
| NCI-H1155 cell | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50=14.3408 μM | SANGER | |||
| NCI-H1304 cell | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50=11.8982 μM | SANGER | |||
| NCI-H1355 cell | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=4.9411 μM | SANGER | |||
| NCI-H1395 cell | Growth inhibition assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50=22.8795 μM | SANGER | |||
| NCI-H1417 cell | Growth inhibition assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50=5.67522 μM | SANGER | |||
| NCI-H1436 cell | Growth inhibition assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50=3.84101 μM | SANGER | |||
| NTERA-S-cl-D1 cell | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=12.8935 μM | SANGER | |||
| JiyoyeP-2003 cell | Growth inhibition assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=36.6284 μM | SANGER | |||
| Click to View More Cell Line Experimental Data | ||||||
Biological Activity
| Description | GSK269962A HCl is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
| In vitro | ||||
| In vitro | GSK269962A completely abolished the actin stress fiber formation induced by angiotensin II in human smooth muscles. Such suppressive effect on actin fiber formation was observed beginning at around 1 μM GSK269962A. GSK269962A induced vasorelaxation in preconstricted rat aorta(tissue baths) with an IC50 of 35 nM. the relaxation induced by GSK269962A is reversible. GSK269962A suppressed IL-6 mRNA transcription and reduced LPS-induced IL-6 and TNF-α protein production in macrophages[1]. | |||
|---|---|---|---|---|
| Cell Research | Cell lines | Human primary smooth muscle cells | ||
| Concentrations | 3 μM | |||
| Incubation Time | 150 min | |||
| Method | Human primary smooth muscle cells were serum-starved(cells were grown on coverslips, and at approximately 50% confluence, they were serum-starved overnight) and stimulated with AngII (100 nM) for 2 h. ROCK inhibitors (3 μM for SB-772077-B or GSK269962A) were added 30 min before AngII stimulation, and cells were fixed and stained with rhodamine phalloidin. Confocal images of actin stain were obtained. | |||
| In Vivo | ||
| In vivo | Oral administration of GSK269962A produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. The reduction of blood pressure was acute and substantial. The maximal effect on blood pressure was observed approximately 2 h after oral gavages. The reduction of blood pressure was accompanied by an acute, dose-dependent increase in heart rate, presumably due to the activation of baroreflex mechanism[1]. ROCK inhibition with the use of GSK 269962 in the 10 mg/kg dose, in turn, triggered an increase in VV(voided volume), PVR(post-void residual), VT(volume threshold), VE(voiding efficiency), ICI(intercontraction interval), BC(bladder compliance), and VTNVC(volume threshold to elicit NVC). The inhibition of the ROCK pathway through GSK 269962 appeared to have no effect on either HR(heart rate), SBP(systolic blood pressure), MBP(systolic blood pressure), or DBP(diastolic blood pressure)[2]. NVC:nonvoiding contractions. | |
|---|---|---|
| Animal Research | Animal Models | female Wistar rats |
| Dosages | 5 or 10 mg/kg | |
| Administration | intra-arterially | |
Chemical Information & Solubility
| Molecular Weight | 607.06 | Formula | C29H30N8O5.HCl |
| CAS No. | 2095432-71-4 | SDF | Download GSK269962A HCl SDF |
| Smiles | CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6.Cl | ||
| Storage (From the date of receipt) | |||
|
In vitro |
DMSO : 100 mg/mL ( (164.72 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.) Ethanol : 28 mg/mL Water : Insoluble |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
Preparing Stock Solutions
Molarity Calculator
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
* Indicates a Required Field
Tags: buy GSK269962A HCl | GSK269962A HCl supplier | purchase GSK269962A HCl | GSK269962A HCl cost | GSK269962A HCl manufacturer | order GSK269962A HCl | GSK269962A HCl distributor
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.